These conditions may worsen until remission is achieved. Effexor and Lexapro therapy may increase suicidal ideation and thoughts among teens and young adults, especially in the early stages of treatment before any type of remission is achieved. These patients must be monitored closely, and a change may be necessary if symptoms suddenly arise or get worse. Serotonin syndrome has been associated with the use of Effexor, Lexapro, and other similar antidepressant medications.
It is associated with too much free serotonin and can cause increased heart rate, agitation, and dizziness. The risk of serotonin syndrome is increased when other serotonergic drugs are used with Effexor or Lexapro. Stopping these medications suddenly may lead to withdrawal symptoms such as headaches, dizziness, fatigue, and irritability.
Effexor is a prescription antidepressant medication used in the treatment of major depression and generalized anxiety disorder. It works by increasing free serotonin and norepinephrine. Lexapro is available in immediate and extended-release tablets, and extended-release capsules. Lexapro is a prescription antidepressant medication used in the treatment of major depression and generalized anxiety disorder. It works by increasing free serotonin. Lexapro is available as an oral tablet and an oral solution.
While both Effexor and Lexapro treat depression and anxiety, they are not the same. Effexor blocks the reuptake of both serotonin and norepinephrine in the neuronal synapse, while Lexapro blocks only serotonin reuptake.
Effexor and Lexapro have been shown to be comparable in terms of efficacy in treating depression, however, studies suggest that Lexapro may be easier to tolerate. Patients on Lexapro are less likely to discontinue treatment early. The Food and Drug Administration FDA considers both Effexor and Lexapro to be in pregnancy category C, meaning there have not been adequate human studies to determine safety. The use of these drugs should be limited to use when the benefits clearly outweigh the risks.
Both Effexor and Lexapro should be avoided in breastfeeding mothers as well. Alcohol can increase the adverse effects of both Effexor and Lexapro. Drinking alcohol while taking these drugs can cause significant psychomotor impairment, and for this reason, patients are advised to avoid alcohol if taking these drugs.
Effexor has been shown to be just as effective, if not more, than most other antidepressant drugs. However, it may be more difficult to tolerate for patients. Your doctor will decide which treatment option is best for you. Venlafaxine is the generic name of Effexor, which is a brand name product. Generic venlafaxine products are considered substitutable for Effexor by the FDA. While some patients may experience somnolence while on Effexor, it is also known to cause agitation and tremor in some patients.
Talk with your physician to determine if this drug may be right for you. Amnesia has been reported in a small number of patients taking Effexor products. If you notice this adverse event, let your prescriber know immediately as a change in therapy may be warranted. Skip to main content Search for a topic or drug.
Effexor vs. Lexapro: Differences, similarities, and which is better for you. By Kristi C. Torres, Pharm. Updated on May. SF scores of the two groups before and after treatment. Table III. SERS ratings of the two groups after treatment.
Comparison of the SERS ratings using a t-test,. SERS, side effects of antidepressants scale. Table IV. Comparison of the clinical efficacies of the two treatment programs.
Comparison of the costs of the two groups Starting from the initial treatment, the treatment costs of the venlafaxine group were greater those of the citalopram group at each observation time point. Table V. Comparison of the treatment costs of the two groups.
Time Venlafaxine group Citalopram group Week 0 Cost-effect analysis Cost-effect analysis was performed to balance the cost and the effect and find an optimal point between them by linking the ratios of the cost and effect together. Table VI. Cost-effect analysis of the two groups. Discussion GAD is a common clinical, chronic and recurring psychological disorder handled in general hospitals. References 1. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during — an epidemiological survey.
The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol. Phamacological treatment of generalized anxiety disorder.
Expert Opin Pharmacother. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry. Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of Generalized Anxiety Disorder. Int J Neuropsychopharmacol. Do antidepressants reduce the burden imposed by depression on employers?
CNS Drugs. American Psychiatric Association. IV Edition. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res. Eddama O, Coast J. A systematic review of the use of economic evaluation in local decision-making.
Health Policy. The biological basis of panic disorder. J Clin Psychiatry. Cost-effectiveness of venlafaxine for the treatment of depression and anxiety. Bibliographic review.
Actas Esp Psiquiatr. In Spanish. Articles from Experimental and Therapeutic Medicine are provided here courtesy of Spandidos Publications. Support Center Support Center. External link. Please review our privacy policy. Treatment groups were similar in terms of demographics and baseline psychiatric assessments.
In the primary analysis, there was no statistical difference between groups. The group with a baseline HAM-D21 total score of did not differ significantly in any efficacy parameters. AEs were reported by Overall discontinuation rates were
0コメント